Gen­er­a­tive AI biotech part­ners with can­cer cen­ter in bid to speed up CAR-T de­vel­op­ment in sol­id tu­mors

One of the biggest star­tups us­ing gen­er­a­tive AI to de­sign pro­tein-based ther­a­pies is bet­ting its tech­nol­o­gy may help crack one of the tough­est prob­lems in cell ther­a­py: get­ting CAR-T cells to tar­get sol­id tu­mors.

Gen­er­ate:Bio­med­i­cines an­nounced Wednes­day morn­ing that it struck a col­lab­o­ra­tion with Roswell Park Com­pre­hen­sive Can­cer Cen­ter in Buf­fa­lo, NY, to co-de­vel­op up to three CAR-T cell ther­a­pies for ovar­i­an can­cer and oth­er sol­id tu­mors. The two groups will equal­ly split the cost of de­sign­ing and de­vel­op­ing the treat­ments and any prof­its if they prove suc­cess­ful.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER